Regulating Pleasure: Choosing Regimes for Psychoactive Drugs Peter Reuter University of Maryland 1.

Slides:



Advertisements
Similar presentations
Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.
Advertisements

2 emcdda.europa.eu European drug report package A comprehensive analysis on the drugs problem in Europe.
 Centre for Drug Misuse Research Glasgow Scotland From Harm Reduction to Abstinence: A Journey in Drug Treatment Pol From Harm Reduction to Abstinence:
SOFT DRINK TAXATION: LEGAL CONSIDERATIONS IN INTERNATIONAL AND DOMESTIC LAW Barbara von Tigerstrom College of Law University of Saskatchewan.
The Health Implications of Raising the Minimum Age for Purchasing Tobacco Products Eric N. Lindblom Director, Office of Policy Center for Tobacco Products,
Llad Phillips 1 Casual Users, Substance Abusers, and Public Policy The War On Drugs.
The War on Drugs: Methamphetamine, Public Health and Crime Carlos Dobkin, Nancy Nicosia.
Forsigtighedstilgang – gevinst eller stopklods Precautionary Principle good or bad for innovation Bjorn Gaarn Hansen Head of Unit: Chemicals Directorate:
© 2012 by Pearson Higher Education, Inc Upper Saddle River, New Jersey All Rights Reserved © 2013 by Pearson Higher Education, Inc Upper Saddle River,
New-Product Development and Product Life-Cycle Strategies 9 Principles of Marketing.
Risk Management and Strategy Prioritisation Intelligence Step 8 - Risk Management and Strategy Prioritisaiton Considering the risks associated with action.
Chemicals Management in a Transatlantic Perspective Henrik Selin November 10, 2008.
Title of Presentation Keeping Them Connected Presentation by Peter Norden, A.O. Melbourne Law School Saint Monica’s College Workshop Epping, 18 th May.
1 Minority SA/HIV Initiative MAI Training SPF Step 3 – Planning Presented By: Tracy Johnson, CSAP’s Central CAPT Janer Hernandez, CSAP’s Northeast CAPT.
Presented By: Tracy Johnson, Central CAPT
Llad Phillips 1 Casual Users, Substance Abusers, and Public Policy The War On Drugs.
1 Consent for treatment A summary guide for health practitioners about obtaining consent for treatment Bridie Woolnough Resolution Officer Health Care.
ESPAD – are young Europeans getting more alike? Björn Hibell EMCDDA Conference Identifying Europe's Information needs for effective drug.
Canadian E-cigarette Regulation Presentation by Reza B.
Legalizing Marijuana Alexis Timpson. Current Marijuana Conditions Current Laws Support for Legislation Politics Medical Uses.
Drug Use. Substance Abuse -any unnecessary or improper use of chemical substance for non medical purposes. –Overuse –Multiple use of a drug –Use of illegal.
Substance Abuse In the Workplace
Illegal drugs Marijuana – otherwise known as ‘dope,’ ‘weed,’ ‘hash,’ ‘skunk,’ ‘grass,’ ‘solid’etc. Do you know what class of drug the Government classifies.
CJ411-Chat 9 By: Amy Ng, ABD. Objectives Unit Reminders Decriminalization Harm reduction.
Harm Reduction Presented by Mike Nielsen. Introduction Brief History Brief History Definition Definition Relationship to Therapy Relationship to Therapy.
Polydrug use challenges – European experience International Conference: New trends in drug use: facts and solutions, Parliament of the Republic of Vilnius.
THE POLITICAL ECONOMY OF DRUG TRAFFICKING
Annual report 2010: the state of the drugs problem in Europe.
Trends and developments Selected trends and some insights in prevention Vilnius, 12 November 2014 Roland Simon.
Overview of Drug Control in Foreign Countries. Drug Control in EU A. Policy Trends ■ Decriminalisation of possession of small amount of drugs for personal.
Copyright (c) Pearson Education 2010 Drugs, Behavior, and Modern Society SIXTH EDITION Charles F. Levinthal Chapter 2 Drug-taking Behavior: The Personal.
An overview of European trends and developments Roland Simon ECAD Meeting 2011, Varna.
Case study: alcohol and tobacco Professor Christine Godfrey Department of Health Sciences, University of York.
PSY 302: Substance Abuse Chapter 12:
USE AND ABUSE PRESCRIPTION, NON- PRESCRIPTION, AND ILLEGAL DRUGS.
INSTITUTIONS FOR COMMITMENT AND CONSISTENCY Sylvia I. Karlsson International Environment Forum Consumer Citizenship Network Third International Conference.
© 2009 McGraw-Hill Higher Education. All rights reserved. Drug Products and Their Regulations.
DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.
© Copyright 2011, Pearson Education, Inc. All rights reserved. Chapter 2 Drug-Taking Behavior: The Personal and Social Concerns.
Harvesting Global Learning on Electronic Nicotine Delivery Systems to Inform U.S. Research, Surveillance and Policy JUNE 6-7, 2015 New Zealand A/Professor.
For Internal Use Only NBRC4Y
Should marijuana be legalized?. How and When this controversy started  Use of marijuana became a problem in the 1930s in the U.S.  1937: Laws passed.
1 THE POLITICAL ECONOMY OF DRUG TRAFFICKING INTRODUCTION 1. Pervasiveness of issue 2. Typicality? Or an extreme case? 3. Categorizing “illicit drugs”—
The Newfoundland and Labrador Alliance for the Control of Tobacco (ACT) and the Non-Smokers’ Rights Association/Smoking and Health Action Foundation Presenter:
Cannabis use in the Americas Slides for presentation at NIDA International Forum.
NPS and Importance of Information Sharing Dr Richard Stevenson A&E Department, Glasgow Royal Infirmary Dr Hazel Torrance Forensic Medicine and Science.
{ Binge drinking in Australia Especially for teenagers.
Compassionate use programs and the European regulatory system Filip Josephson M.D., Ph.D. Clinical Assessor.
New Psychoactive Substances: an overview of the evidence Isla Wallace, Social Researcher Drugs Research Team
1 THE POLITICAL ECONOMY OF DRUG TRAFFICKING INTRODUCTION 1. Pervasiveness of issue 2. Challenges for research 3. Categorizing “illicit drugs”— Marijuana.
Objectives and results Thinking concepts #3. Which actions will bring about the best results?  Change does not just happen  If cellphone use in cars.
1 Effects on smoking cessation of a national strategy to maximise NRT usage: the UK experience Robert West University College London WCTOH July 2006 Washington.
Addressing the Federal Legalization of Cannabis Briefing to Standing Committee on Priorities and Planning June 7, 2017.
Legal and Illegal Drugs
Proposition 64 County Behavioral Health Directors Association
Drug addiction: Therapeutic problems in everyday clinical practice
Addressing the Federal Legalization of Cannabis Briefing to Standing Committee on Priorities and Planning June 7, 2017.
Misdiagnosis of a Problem: Why Can’t We Solve the Problem of Addiction Jon Caulkins RAND Drug Policy Research Center Carnegie Mellon University Heinz.
Presentation on Illegal Drugs
Proposition 64 County Behavioral Health Directors Association
The social epidemiology of alcohol and drug use among Israeli school-aged children: Recent developments and current challenges Prof. Yossi Harel-Fisch.
Legalizing Marijuana in New Mexico: Protecting Our Youth & Public Health. Emily Kaltenbach April 24, 2018.
May 8, 2018 Nova Scotia Law Enforcement Perspective
Comparison of data from WBE with other sources
Marijuana: Do the Laws Need to Change?
Youth Driving Under the Influence of Marijuana
MARIJUANA IN WASHINGTON
Chapter 5 Promoting youth health and wellbeing
ADDICTION
Skopje, 21 November 2017, General Population Survey results– launch
Presentation transcript:

Regulating Pleasure: Choosing Regimes for Psychoactive Drugs Peter Reuter University of Maryland 1

Motivation Marijuana legalization now serious policy option – US movement driven mostly by dissatisfaction with apparently tough enforcement – Also potential state revenues – Importance of substitution with other substances New psychoactive substances (NPS) present similar issues: – How will NPS affect total mix of psychoactive substances? – Are gains from allowing legal distribution merely elimination of the harms associated with the prohibited? 2

New, attractive psychoactive substances are produced increasingly frequently …. Single convention listed 85 prohibited substances in 1961 and 282 by 1995 – Shulgin: 2 psychedelics in 1900 (mescalin and marijuana), 20 in 1950, 200 in 2000 Growing number of competent chemists – Particularly in countries with weak regulations Technologies make innovation easier Globalization (of course) 3

…and present a regulatory challenge Require decisions when scientific knowledge limited Though they are not intended as medicines current system (US, Europe, Australia) treats them as potential therapeutic drugs – Either enter pharmacopeia or prohibited Is there an alternative system that would produce results reflecting more elements of social wellbeing? 4

Recent experiences with new substances follow common pattern Substance enters grey market through variety of marketing channels – Internet, boutique stores etc., with false label – E.g. “not intended for human consumption” Increasing number of reports of some adverse effects A small number of highly publicized fatalities with confused etiology Review leads to prohibition 5

NPS often linked Ecstasy market generating low quality drugs – Often contains other active ingredients Mephedrone developed partially to provide reliable source of Ecstasy-like experiences Following mephedrone scheduling in UK, naphyrone developed – alternative means of dumping mephedrone through mislabeling 6

ACMD reasoning for scheduling Naphyrone Exculpatory: – “[N]o confirmed cases of acute toxicity associated with the use of naphyrone.” – “[No known] relationship between naphyrone and anti-social behaviour or acquisitive crime.” However – Drugs marketed as naphyrone often contained other drugs – Large differences in dose size between naphyrone and the drugs often sold under that name – Effective dose size of naphyrone so small (25 mg.) that many users likely to take dangerously high doses All these considerations distinct from clinical trials outcomes 7

BZP in New Zealand best studied NPS BZP not prohibited when it became popular and widely promoted in NZ ca law created restrictions on promotion and banned sales to under 18 – Widely flouted – Tacit permission for production and sales to adults Survey in 2007 found 5.6% used in previous 12 months (4 th most popular) – Many believed drug was approved by government Government scheduled drug in 2008 – Large decline in prevalence PSA passed in 2013 – Full implementation only begins in Nov

Challenge of establishing risk for PSA Six components – Toxicological effects – Risk to public health – Potential to cause death – Potential to create dependence – Likelihood of misuse – Appeal to vulnerable populations What acceptable level of risk in each domain? – What is cost of assessing? Small country not ideal for initial test because such testing has high fixed costs 9

EU lists broad set of criteria for assessing new substance (2005) “An assessment of risks caused by use of, manufacture of, traffic in a new substance as well as the potential involvement of organized crime.” The risks to be assessed include social and health risks as well as the consequences of potential control measures.” 10

Implemented system much simpler EU list strains analytic capacity – For example, how could organized crime involvement be predicted? Instead uses standard assessment of drug scheduling decisions: Is this substance safe and medically useful? Cannot pass the test of being the preferred treatment for a specified medical condition 11

12

Decisions must be made on meager scientific evidence Example: “There is an absence of standard safety pharmacology and toxicology data. …..Many BZP tablets and capsules also contain TFMPP (1-(3-trifluoromethylphenyl) piperazine)…..most users consume BZP with alcohol as well as other psychoactive substances.” (EMCDDA, 2007; p.4) Who has incentive to fund large scale studies of epidemiology and effects of drug? On what basis does the regulator project the future trajectory of use of BZP and related substances? – Hard/impossible to do even with well studied substance such as cocaine and alcohol 13

Other regulatory complications If, despite label warnings, it is predictable that users will take alcohol simultaneously with BZP, should that figure in the risk assessment? Prohibition may cause additional harms but how can they be projected for analysis in a public and transparent fashion? – Harms from prohibition very drug-specific 14

Problem modest in most countries UK 1700 treatment entries in 2013/14 out of 64,000 total treatment entries – 52 deaths out of 1699 total European Commission lists 80 new substances for review in 2013 Many NPS briefly prominent but few last long – Most turn out to be dangerous or unattractive – “It may be that the market, to some extent, regulates itself with less effective or more harmful NPS only being seen for very short periods of time or in a limited number of countries” (Home Office, 2014) US has scheduled only 71 new substances (plus analogues) (Caulkins and Coulson) – Synthetic cannabinoids may present more serious challenge – 11.4% of high school seniors reported past year use in

New Substances in Europe (EEWS) 16

Last year prevalence of NPS (Britain, year olds) 2009/102010/112011/122012/132013/14 MephedroneN/A SalviaN/A GBL/GHB N/A Spice N/A BZP N/A 17

18

19

How should Marijuana be regulated? Set aside medical uses – Separate regime operating in many jurisdictions Marijuana has known risks – Addictive – Source of accidents – Early, heavy use has long-term and serious behavioral consequences (Dunedin study) Would fail test under EU NPS regime 20

Marijuana legalization case rests primarily on harms averted Police use marijuana possession arrests to control minority communities Prohibition generates large black markets – Corruption and violence in Mexico Buying marijuana increases youth contact with other illegal drugs Concern about rising THC content – Declining CBD Prohibition fails to make drug expensive or inaccessible Government revenue the one positive element 21

Marijuana readily available to youth Drug cocaine amphetamines heroin Marijuana Percent of high school seniors reporting drug readily available or somewhat available

Wide range of possible legal regimes Potential regimes – Grow your own (Colorado, Uruguay) – Clubs (Spain, Uruguay) – State monopoly (no advertizing) – Private enterprise (Colorado, Washington) Three policy decisions drive consumption – Price – Promotion – Access 23

How will legalization affect public health? Prevalence will rise – Price and access effects Public health consequences reflects more than prevalence – Product innovation also important – Ratio of THC to CBD Substitution for heavy drinking critical – Current research on relationship ambiguous – Relationship may be different short- and long-term Caution: knowledge about constituent elements of marijuana probably similar to knowledge about tobacco in

Conclusions Regulatory decisions are made at a stage when some harms will be known but assessment will be very incomplete Current system gives no weight to pleasures of drug use nor to potential substitution for a more harmful substance (legal or illegal) – Ignores the realities of contemporary life – What if a less harmful substitute for alcohol were available? Thus responsible decision makers will have no benefits to balance against known risks Result is that it is unlikely that any NPS will be allowed 25